← Leaderboards
Baek Kim
University Of Rochester
$21,816,663
Attributed
$26,244,083
Total exposure
14
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$26,244,083 · 14
By mechanism
R01$24,817,628 · 10
R21$811,300 · 2
R56$390,000 · 1
R29$225,155 · 1
Top collaborators
- David Sung-Wen Yu9 shared
- Louis M Mansky6 shared
- Steven E Patterson6 shared
- Jyothi Rengarajan2 shared
- Bashar Samih Staitieh2 shared
- Raymond F. Schinazi1 shared
Most similar at University Of Rochester
Same institution · by research overlap
- Darwin J Operario$159,140
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsHiv-1ViralMutationProteinsBiochemicalCd4 Positive T LymphocytesMediatingMacrophagePathogenesisReportingDna BiosynthesisKineticsRna-Directed Dna PolymeraseInfectionVirusSeriesBaseCell TypeInterphase CellTripolyphosphateInsightBindingMicroglia
Grant awards (77)
Investigating alveolar macrophages in PLWH as targets for HIV persistence, residual inflammation and immune activation$1,030,790
R01 · FY2025 · AI
Structural and Chemical Analysis of Highly Potent ALLINI Platform$459,314
R01 · FY2025 · AI · contact PI
Lentivirus Replication Strategy and Pathogenesis$445,033
R01 · FY2025 · AI · contact PI
SAMHD1 mediated dNTP regulation and HIV in myeloid cells$385,206
R01 · FY2025 · AI · contact PI
Investigating alveolar macrophages in PLWH as targets for HIV persistence, residual inflammation and immune activation$1,010,290
R01 · FY2024 · AI
Elucidating SAMHD1 in DNA Double-Strand Break Repair$484,800
R01 · FY2024 · CA
Structural and Chemical Analysis of Highly Potent ALLINI Platform$464,005
R01 · FY2024 · AI · contact PI
Lentivirus Replication Strategy and Pathogenesis$453,473
R01 · FY2024 · AI · contact PI
SAMHD1 mediated dNTP regulation and HIV in myeloid cells$385,755
R01 · FY2024 · AI · contact PI
Elucidating SAMHD1 in DNA Double-Strand Break Repair$117,933
R01 · FY2024 · CA
Elucidating SAMHD1 in DNA Double-Strand Break Repair$54,075
R01 · FY2024 · CA
SAMHD1 mediated dNTP regulation and HIV in myeloid cells$688,870
R01 · FY2023 · AI · contact PI
Elucidating SAMHD1 in DNA Double-Strand Break Repair$500,212
R01 · FY2023 · CA
Lentivirus Replication Strategy and Pathogenesis$461,675
R01 · FY2023 · AI · contact PI
Elucidating SAMHD1 in DNA Double-Strand Break Repair (Supplement)$124,140
R01 · FY2023 · CA
Elucidating SAMHD1 in DNA Double-Strand Break Repair (Supplement)$56,922
R01 · FY2023 · CA
Elucidating SAMHD1 in DNA Double-Strand Break Repair$500,301
R01 · FY2022 · CA
SAMHD1 mediated dNTP regulation and HIV in myeloid cells$415,345
R01 · FY2022 · AI · contact PI
Structural and Chemical Analysis of Highly Potent ALLINI Platform$389,750
R01 · FY2022 · AI · contact PI
Lentivirus Replication Strategy and Pathogenesis$385,498
R01 · FY2022 · AI · contact PI
Elucidating SAMHD1 in DNA Double-Strand Break Repair$510,595
R01 · FY2021 · CA
Structural and Chemical Analysis of Highly Potent ALLINI Platform$389,750
R01 · FY2021 · AI · contact PI
SAMHD1 mediated dNTP regulation and HIV in myeloid cells$386,718
R01 · FY2021 · AI · contact PI
Lentivirus Replication Strategy and Pathogenesis$385,907
R01 · FY2021 · AI · contact PI
Elucidating SAMHD1 in DNA Double-Strand Break Repair$510,674
R01 · FY2020 · CA
Structural and Chemical Analysis of Highly Potent ALLINI Platform$389,750
R01 · FY2020 · AI · contact PI
Lentivirus Replication Strategy and Pathogenesis$386,279
R01 · FY2020 · AI · contact PI
SARS-CoV-2 polymerase inhibitor screening$207,993
R01 · FY2020 · AI · contact PI
SARS-CoV-2 polymerase inhibitor screening$104,001
R01 · FY2020 · AI · contact PI
Structural and Chemical Analysis of Highly Potent ALLINI Platform$389,750
R01 · FY2019 · AI · contact PI
Lentivirus Replication Strategy and Pathogenesis$386,618
R01 · FY2019 · AI · contact PI
SAMHD1 controls dNTP pool and HIV sensitivity to NRTIs$311,220
R01 · FY2019 · AI · contact PI
Structural and Chemical Analysis of Highly Potent ALLINI Platform$403,750
R01 · FY2018 · AI · contact PI
Lentivirus Replication Strategy and Pathogenesis$386,925
R01 · FY2018 · AI · contact PI
SAMHD1 controls dNTP pool and HIV sensitivity to NRTIs$311,220
R01 · FY2018 · GM · contact PI
SAMHD1 controls dNTP pool and HIV sensitivity to NRTIs$59,852
R01 · FY2018 · GM · contact PI
Replicational Fidelity and Lentivial Pathogenesis$390,000
R56 · FY2017 · AI · contact PI
SAMHD1 controls dNTP pool and HIV sensitivity to NRTIs$311,220
R01 · FY2017 · GM · contact PI
HIV Reverse Transcriptase-Mediated Mutagenesis$578,622
R01 · FY2016 · GM
Replicational Fidelity and Lentiviral Pathogenesis$404,051
R01 · FY2016 · AI · contact PI
SAMHD1 controls dNTP pool and HIV sensitivity to NRTIs$311,220
R01 · FY2016 · GM · contact PI
Equipment Admin supplement to SAMHD1 controls dNTP pool and HIV sensitivity to NRTls$115,000
R01 · FY2016 · GM · contact PI
HIV Reverse Transcriptase-Mediated Mutagenesis$578,622
R01 · FY2015 · GM
Replicational Fidelity and Lentiviral Pathogenesis$387,900
R01 · FY2015 · AI · contact PI
SAMHD1 controls dNTP pool and HIV sensitivity to NRTIs$294,300
R01 · FY2015 · GM · contact PI
Replicational Fidelity and Lentiviral Pathogenesis$102,687
R01 · FY2015 · AI · contact PI
HIV Reverse Transcriptase-Mediated Mutagenesis$578,622
R01 · FY2014 · GM
Replicational Fidelity and Lentiviral Pathogenesis$387,900
R01 · FY2014 · AI · contact PI
SAMHD1 controls dNTP pool and HIV sensitivity to NRTIs$294,300
R01 · FY2014 · GM · contact PI
HIV Reverse Transcriptase-Mediated Mutagenesis$40,363
R01 · FY2014 · GM
HIV Reverse Transcriptase-Mediated Mutagenesis$9,459
R01 · FY2014 · GM
HIV Reverse Transcriptase-Mediated Mutagenesis$591,622
R01 · FY2013 · GM
Replicational Fidelity and Lentiviral Pathogenesis$363,075
R01 · FY2013 · AI · contact PI
SAMHD1 controls dNTP pool and HIV sensitivity to NRTIs$264,870
R01 · FY2013 · GM · contact PI
Replicational Fidelity and Lentiviral Pathogenesis$386,250
R01 · FY2012 · AI · contact PI
Targeting PI3K/Akt Cell Survival Pathway as a Novel Anti-HIV Therapy$339,605
R01 · FY2012 · AI · contact PI
SAMHD1 controls dNTP pool and HIV sensitivity to NRTIs$280,172
R01 · FY2012 · GM · contact PI
SAMHD1 controls dNTP pool and HIV sensitivity to NRTIs$10,126
R01 · FY2012 · GM · contact PI
Targeting PI3K/Akt Cell Survival Pathway as a Novel Anti-HIV Therapy$339,605
R01 · FY2011 · AI · contact PI
Replicational Fidelity and Lentiviral Pathogenesis$337,479
R01 · FY2011 · AI · contact PI
Targeting PI3K/Akt Cell Survival Pathway as a Novel Anti-HIV Therapy$343,035
R01 · FY2010 · AI · contact PI
Replicational Fidelity and Lentiviral Pathogenesis$340,888
R01 · FY2010 · AI · contact PI
Targeting PI3K/Akt Cell Survival Pathway as a Novel Anti-HIV Therapy$346,500
R01 · FY2009 · AI · contact PI
Replicational Fidelity and Lentiviral Pathogenesis$344,331
R01 · FY2009 · AI · contact PI
Replicational Fidelity and Lentiviral Pathogenesis$344,331
R01 · FY2008 · AI · contact PI
Novel oncolytic adenovirus for pancreatic therapy$215,600
R21 · FY2008 · CA · contact PI
Replicational Fidelity and Lentiviral Pathogenesis$351,000
R01 · FY2007 · AI · contact PI
Novel oncolytic adenovirus for pancreatic therapy$123,200
R21 · FY2007 · CA · contact PI
Replication fidelity and lentiviral pathogenesis$275,625
R01 · FY2005 · AI
HIV-1 Vpr Induced dNTP Biosynthesis and DNA Gap Repair$236,250
R21 · FY2005 · AI
Replication fidelity and lentiviral pathogenesis$275,625
R01 · FY2004 · AI
HIV-1 Vpr Induced dNTP Biosynthesis and DNA Gap Repair$236,250
R21 · FY2004 · AI
Replication fidelity and lentiviral pathogenesis$275,625
R01 · FY2003 · AI
Replication fidelity and lentiviral pathogenesis$273,606
R01 · FY2002 · AI
Replication fidelity and lentiviral pathogenesis$5,603
R01 · FY2002 · AI
TESTING REVERSE TRANSCRIPTASE FIDELITY AS A HIV TARGET$113,929
R29 · FY2001 · GM
TESTING REVERSE TRANSCRIPTASE FIDELITY AS A HIV TARGET$111,226
R29 · FY2000 · GM